Clinical characteristics and prognostic analysis of triple‑negative breast cancer patients

Yuan,Na; Meng,Min; Liu,Caigang; Feng,Lu; Hou,Lei; Ning,Qian; Xin,Guohong; Pei,Li; Gu,Shanzhi; Li,Xiao; Zhao,Xinhan

doi:10.3892/mco.2013.230

Clinical characteristics and prognostic analysis of triple‑negative breast cancer patients

Authors:
- Na Yuan
- Min Meng
- Caigang Liu
- Lu Feng
- Lei Hou
- Qian Ning
- Guohong Xin
- Li Pei
- Shanzhi Gu
- Xiao Li
- Xinhan Zhao
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Breast Surgery, Research Unit of General Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Forensic Medicine, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Statistics, University of Illinois at Urbana‑Champaign, Urbana, IL 61820, USA
Published online on: December 20, 2013 https://doi.org/10.3892/mco.2013.230
Pages: 245-251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well‑established that triple‑negative breast cancer (TNBC) is a subtype of breast cancer, characterized by a poor prognosis and aggressive biological behavior. However, the available relevant data on TNBC in non‑western populations are limited. In order to analyze the clinicopathological and molecular biological characteristics and observe survival and prognostic factors, 972 breast cancer patients (156 of whom had TNBC) who received treatment at the First Affiliated Hospital of Medical School of Xi'an Jiaotong University and the First Hospital of China Medical University, between January, 2004 and January, 2007 were retrospectively evaluated. In the univariate analysis, tumor size, TNM stage, axillary lymph node status and recurrence or metastasis were identified as prognostic factors for 7‑year disease‑free survival (DFS) and overall survival (OS). Our multivariate Cox's regression analysis demonstrated that tumor size and axillary lymph node status were significant prognostic factors for 7‑year DFS and OS. Notably, tumor subgroup (TNBC vs. non‑TNBC) was a significant prognostic factor associated with 7‑year DFS and OS in breast cancer. It was suggested that TNBC exhibited a worse 7‑year survival compared with that in non‑TNBC patients, most likely due to its more aggressive behavior and insensitivity to specific therapy.

View Figures

View References

1	Alkis N, Durnali AG, Arslan UY, et al: Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol. 28:1255–1259. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jha K, Shukla M and Pandey M: Survivin expression and targeting in breast cancer. Surg Oncol. 21:125–131. 2012. View Article : Google Scholar : PubMed/NCBI
3	Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
4	Ono M, Tsuda H, Shimizu C, et al: Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 132:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hicks DG, Short SM, Prescott NL, et al: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 30:1097–1104. 2006. View Article : Google Scholar : PubMed/NCBI
6	Oakman C, Viale G and Di Leo A: Management of triple negative breast cancer. Breast. 19:312–321. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yin WJ, Lu JS, Di GH, et al: Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat. 115:325–333. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lin C, Chien SY, Kuo SJ, et al: A 10-year follow-up of triple-negative breast cancer patients in Taiwan. Jpn J Clin Oncol. 42:161–167. 2012.PubMed/NCBI
9	Kurebayashi J, Moriya T, Ishida T, et al: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 16(Suppl 2): S72–S77. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW and Chen DR: Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer. 9:1922009. View Article : Google Scholar : PubMed/NCBI
11	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
12	Rakha EA, El-Sayed ME, Green AR, Lee AH, et al: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
13	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
14	Calza S, Hall P, Auer G, et al: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 8:R342006. View Article : Google Scholar : PubMed/NCBI
15	Kandel MJ, Stadler Z, Masciari S, et al: Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol. 24:5082006.
16	Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
17	Zhang L, Hao C, Dong G and Tong Z: Analysis of clinical features and outcome of 356 triple-negative breast cancer patients in China. Breast Care (Basel). 7:13–17. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tischkowitz M, Brunet JS, Begin LR, et al: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7:1342007. View Article : Google Scholar : PubMed/NCBI
19	Nishimura R and Arima N: Is triple negative a prognostic factor in breast cancer? Breast Cancer. 15:303–308. 2008. View Article : Google Scholar : PubMed/NCBI
20	Khan AM, Sabnani I, Tsang P, et al: Triple-negative early-stage breast cancer in African American women: A fuel to the fire. J Clin Oncol. 26:110392008.
21	Reis-Filho JS, Milanezi F, Steele D, et al: Metaplastic breast carcinomas are basal-like tumours. Histopathology. 49:10–21. 2006. View Article : Google Scholar
22	Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D and Sabri S: Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 29:2852–2858. 2011. View Article : Google Scholar
23	Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al: Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 29:2628–2634. 2011. View Article : Google Scholar : PubMed/NCBI
24	Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
25	Bertucci F, Finetti P, Cervera N, et al: Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66:4636–4644. 2006. View Article : Google Scholar
26	Fadare O, Wang SA and Hileeto D: The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? Hum Pathol. 39:331–336. 2008. View Article : Google Scholar : PubMed/NCBI
27	Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
28	Kaplan HG, Malmgren JA and Atwood M: T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 15:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
29	Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ and Shao ZM: Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat. 115:325–333. 2009. View Article : Google Scholar : PubMed/NCBI
30	Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P and Tan PH: Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 23:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
31	Shah SN, Cope L, Poh W, et al: HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One. 8:e634192013. View Article : Google Scholar : PubMed/NCBI
32	Maire V, Baldeyron C, Richardson M, et al: TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One. 8:e637122013. View Article : Google Scholar : PubMed/NCBI